EMcision develops a radio-frequency technology for the surgical community. The Habib™4X, which treats liver cancer, is n°1 in the hepatic resection devices in United-States.
EMcision and the CTS
With this success the company can currently commercialize and develop new devices to improve care provided to the patient by radio-frequency.
Our products give, for the first time, a non invasive access for the clinicians to the digestive system's deep organs to apply radio-frequencies treatments. With the CTS Santé's help we keep up more effectively our objective which is to improve therapeutic devices to beat biliary tract and pancreas cancers.François PoulinGeneral Director, EMcision International